MONTREAL, CANADA, December 11, 2009 - Technologie Biolactis Inc., a Canadian biotechnology company specializing in the development of lactoceuticals focused on cardiovascular, metabolic and obesity-associated disorders, is pleased to announce the filing of a new patent application protecting the recent discovery of an obesity related metabolic pathway modulation.

Obesity is a chronic disorder of energy imbalance characterized by an excess of energy intake in the long term compared with limited energy expenditure, leading to storage of the excess energy in the form of adipose tissue. Obesity contributes directly to numerous dangerous co-morbidities, including type 2 diabetes, cardio-metabolic diseases, hepatic disorders, cardiovascular disease, inflammatory diseases, premature aging, and some forms of cancer. Obesity has reached epidemic proportions globally with more than 1 billion adults overweight, at least 300 million of them clinical obese.

Following the genomic analysis of the mechanism of action, the bioactive ingredients of BiolActis, called MPM (Malleable Protein Matrix), demonstrated the capacity to modulate specific nuclear receptor, the peroxisome proliferator activated receptors (PPARs), and some biological pathway associated to obesity.

It has been well established that PPARs agonists are key players in establishing strategy to fight obesity. The PPARs are important regulators of carbohydrate and lipid metabolism, cell growth and differentiation, immune-regulation and the inflammatory response. Biological processes modulated by PPARs include, for example, plasma lipid transport and fatty acid catabolism, regulation of insulin sensitivity and blood glucose levels, inflammatory response, weight control and body composition.

"Since it has been well established that PPARs play a major roles in energy homeostasis and other significant biological processes in the human body, they are considered to be important molecular targets for treatment of obesity and metabolic related disorders" says Dr. Jean-François Lapointe, Clinical Director of BiolActis.

" The lack of therapeutic effectiveness, coupled with the spiralling obesity epidemic, positions the "treatment of obesity" as one of the largest and most urgent unmet health condition. There is, therefore, a real and continuing need for the development of improved alternatives that helps or prevents obesity related disorders with a natural approach" as stated by Dr. Pierre Lemieux, President & CEO of BiolActis.

Furthermore, Dr. Éric Simard, Vice-President, Operations at BiolActis mentioned: "In time, this new discovery will lead to the development of innovative and multiple value-added commercial applications targeted for individuals concerned with their weight and calorie intake. Since BiolActis is producing its ingredients from natural source, the Company shall be able to market these products as functional foods or dietary supplements which will accelerate the development and facilitate access to international markets.

For more information please contact:

Pierre Lemieux, CEO

Technologie Biolactis Inc.

500, Boul. Cartier Ouest, Suite 128

Laval, Québec, Canada  H7V 5B7

Tel.: (450) 781-1253 #1303